Lead sponsor
Pfizer
52 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
52
Trials led
0
Ongoing
8,884
Total enrollment
1,309
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
18
Phase 2
18
Phase 2/3
1
Phase 3
10
Not applicable
5
Trials by status
Completed
35
Terminated
16
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsAlzheimer's diseasePh 3Terminated1,100
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer's diseasePh 3Terminated901
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 3Completed742
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's DiseaseAge ≥50Ph 3Terminated649
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer DiseaseAlzheimer's diseasePh 2Terminated526
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer's diseasePh 3Terminated494
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's DiseaseMMSE 14-26Ph 2Completed402
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's DiseaseAlzheimer's diseaseN/ACompleted300
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's DiseaseAlzheimer's diseasePh 2/3Completed250
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing HomesAlzheimer's diseasePh 3Completed249
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed198
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer's diseasePh 3Terminated198
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed191
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On DonepezilAlzheimer's diseasePh 2Terminated186
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed160
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed160
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Terminated160
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed DementiaMultiple dementia etiologiesPh 3Terminated149
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's DiseaseAlzheimer's diseasePh 1Completed88
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's DiseaseStudy partner/caregiver requiredPh 3Terminated86
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed86
Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed66
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's DiseaseAlzheimer's diseasePh 2Completed63
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous BapineuzumabAlzheimer's diseasePh 2Terminated62
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Terminated53
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's DiseaseAge 50-90Ph 1Completed52
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsAge 18-55Ph 1Completed45
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed40
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCIMMSE 24-30N/ACompleted38
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed37
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed36
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersAge 18-55Ph 1Completed36
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed32
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 MetabolizersAge 18-55Ph 1Completed24
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionHealthy volunteersPh 1Completed20
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)Age 18-55Ph 1Completed20
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed20
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinAge 50-85Ph 1Completed19
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's DiseaseAlzheimer's disease · APP mutation requiredN/ATerminated18
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy VolunteersAlzheimer's diseasePh 1Completed17
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed15
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's DiseaseMMSE 18-26Ph 1Completed15
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsAge 18-55Ph 1Completed14
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanAge 18-55Ph 1Completed14
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy SubjectsAge 18-55Ph 1Completed12
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Terminated9
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed8
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's DiseaseAge ≥50Ph 3Terminated5
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Diseasemild-to-moderate ADPh 2Withdrawnnot disclosed